News - Page 73 - Psychedelic Alpha

Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.

Read more about the article Small Pharma Reports Fiscal Third Quarter 2023 Highlights

Small Pharma Reports Fiscal Third Quarter 2023 Highlights

Post published:January 25, 2023
Post category:Press Release

Read more about the article Hebrew University’ Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023

Hebrew University’ Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023

Post published:January 25, 2023
Post category:Press Release

Read more about the article Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder

Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder

Post published:January 25, 2023
Post category:Press Release

Read more about the article GH Research Provides Business Updates and Highlights Key Upcoming Milestones

GH Research Provides Business Updates and Highlights Key Upcoming Milestones

Post published:January 25, 2023
Post category:Press Release

Read more about the article Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25

Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25

Post published:January 24, 2023
Post category:Press Release

Read more about the article Diamond Therapeutics Announces Health Canada Approval of Phase 2 Clinical Trial with Low-Dose Psilocybin

Diamond Therapeutics Announces Health Canada Approval of Phase 2 Clinical Trial with Low-Dose Psilocybin

Post published:January 24, 2023
Post category:Press Release

Read more about the article Panel: Three Psychedelics Companies that Raised in 2022

Panel: Three Psychedelics Companies that Raised in 2022

Post published:January 24, 2023
Post category:2022 Year in Review

Read more about the article Panel: Psychedelic VCs Reflect on 2022

Panel: Psychedelic VCs Reflect on 2022

Post published:January 24, 2023
Post category:2022 Year in Review

Read more about the article Psyence and Eden Labs Announce Extraction and Product Development Collaboration

Psyence and Eden Labs Announce Extraction and Product Development Collaboration

Post published:January 24, 2023
Post category:Press Release

Read more about the article Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer

Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer

Post published:January 23, 2023
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.